Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
High pressure (hyperbaric) oxygen resolves severe breathing difficulties in COVID-19 patients much more quickly than standard therapy, taking an average of 3 rather than 9 days, reveal the results of a small comparative clinical trial published online in Emergency Medicine Journal.
Researchers have screened several compounds that could show the ability to inhibit SARS-CoV-2.
A review published in Chemo-Biological Interactions has focused on the prevalence of COVID-19 in CVD patients associated with ACE2 mechanisms.
Researchers focussed on the S-learner strategy of estimating the conditional average treatment effect.
Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body's first lines of defense against pathogens and compromising the multiple beneficial effects our microbiota has for our health.
Antibiotics alone likely cannot overcome the complex factors that cause stunted growth and perpetuate the cycle of poverty in the developing world, new research suggests.
A new study describes the nature and extent of the shift in dispensing these medications, as well as its eventual outcome.
A new study aimed to determine the course of SARS-CoV-2 infection in children suffering from rheumatic disease and were receiving bDMARD treatment.
There remains a significant need for new and effective drugs that can be used to treat COVID-19.
A common antibiotic has been found to reduce low birth weight and premature births, if taken during pregnancy, in countries where malaria is endemic, according to a research review.
India continues to grapple with the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, the country has reported over one million new cases for the past 28 days.
Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data showing that herbal medicines have potent activity in test tubes compared to pharmaceuticals commonly-prescribed for the treatment of Bartonella henselae, a bacterium believed to be carried by ticks and the cause of cat scratch fever.
The first wave of COVID-19 in 2020 in India saw a substantial increase in the sale of antibiotic formulations used in adults and adolescents, especially azithromycin, says a study.
A UC San Francisco study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease.
One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.
A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.
However, a fascinating new study posted to the medRxiv* preprint server suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic.
Most medications being tested today in clinical trials for the treatment of coronavirus disease 2019 (COVID-19) have been repurposed from other indications. These are typically not tested in pregnant women. A new study, published in the journal PLOS ONE, summarizes what is known about the safety of these drugs in this group.
A record of medicine utilization patterns assembled by an interdisciplinary team of researchers at the University of California, Irvine and the UC San Diego School of Medicine reveals the thought, care and scientific rigor clinicians at UC Health medical centers applied in their treatment of patients with COVID-19 in 2020.
Hertz Fellow Ravi Sheth says his lab in the Brooklyn Navy Yard is "like a Willy Wonka factory of microbes" geared toward improving the taste and safety of food and beverages.